Gut-Microbiota Dysbiosis in Stroke-Prone Spontaneously Hypertensive Rats with Diet-Induced Steatohepatitis

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2023 Mar 11

PMID 36902037

Authors

Shini Kanezawa

Mitsuhiko Moriyama

Tatsuo Kanda

Akiko Fukushima

Ryota Masuzaki

Reina Sasaki-Tanaka

Akiko Tsunemi

Takahiro Ueno

Noboru Fukuda

Hirofumi Kogure

Affiliations

Soon will be listed here.

Abstract

Metabolic-dysfunction-associated fatty-liver disease (MAFLD) is the principal worldwide cause of liver disease. Individuals with nonalcoholic steatohepatitis (NASH) have a higher prevalence of small-intestinal bacterial overgrowth (SIBO). We examined gut-microbiota isolated from 12-week-old stroke-prone spontaneously hypertensive-5 rats (SHRSP5) fed on a normal diet (ND) or a high-fat- and high-cholesterol-containing diet (HFCD) and clarified the differences between their gut-microbiota. We observed that the ratio in both the small intestines and the feces of the SHRSP5 rats fed HFCD increased compared to that of the SHRSP5 rats fed ND. Notably, the quantities of the 16S rRNA genes in small intestines of the SHRSP5 rats fed HFCD were significantly lower than those of the SHRSP5 rats fed ND. As in SIBO syndrome, the SHRSP5 rats fed HFCD presented with diarrhea and body-weight loss with abnormal types of bacteria in the small intestine, although the number of bacteria in the small intestine did not increase. The microbiota of the feces in the SHRSP5 rats fed HFCD was different from those in the SHRP5 rats fed ND. In conclusion, there is an association between MAFLD and gut-microbiota alteration. Gut-microbiota alteration may be a therapeutic target for MAFLD.

Citing Articles

Pruritus in Chronic Cholestatic Liver Diseases, Especially in Primary Biliary Cholangitis: A Narrative Review.

Kanda T, Sasaki-Tanaka R, Kimura N, Abe H, Yoshida T, Hayashi K Int J Mol Sci. 2025; 26(5).

PMID: 40076514 PMC: 11900276. DOI: 10.3390/ijms26051883.

Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma.

Scarpellini E, Scarlata G, Santori V, Scarcella M, Kobyliak N, Abenavoli L Biomedicines. 2024; 12(8).

PMID: 39200261 PMC: 11351762. DOI: 10.3390/biomedicines12081797.

Muscle Cramps in Outpatients with Liver Diseases in Tokyo, Japan.

Kanda T, Sasaki-Tanaka R, Matsumoto N, Arima S, Kanezawa S, Honda M Medicina (Kaunas). 2023; 59(9).

PMID: 37763625 PMC: 10532783. DOI: 10.3390/medicina59091506.

References

Huang D, Downes M, Evans R, Witztum J, Glass C, Loomba R . Shared Mechanisms between Cardiovascular Disease and NAFLD. Semin Liver Dis. 2022; 42(4):455-464. PMC: 9828940. DOI: 10.1055/a-1930-6658. View

Higuchi T, Moriyama M, Fukushima A, Matsumura H, Matsuoka S, Kanda T . Association of mRNA expression of iron metabolism-associated genes and progression of non-alcoholic steatohepatitis in rats. Oncotarget. 2018; 9(40):26183-26194. PMC: 5995254. DOI: 10.18632/oncotarget.25488. View

Moriya T, Kitamori K, Naito H, Yanagiba Y, Ito Y, Yamagishi N . Simultaneous changes in high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis and those underlying molecular mechanisms in novel SHRSP5/Dmcr rat. Environ Health Prev Med. 2012; 17(6):444-56. PMC: 3493629. DOI: 10.1007/s12199-012-0273-y. View

DeSantis T, Hugenholtz P, Larsen N, Rojas M, Brodie E, Keller K . Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol. 2006; 72(7):5069-72. PMC: 1489311. DOI: 10.1128/AEM.03006-05. View

Di Ciaula A, Bonfrate L, Portincasa P . The role of microbiota in nonalcoholic fatty liver disease. Eur J Clin Invest. 2022; 52(7):e13768. DOI: 10.1111/eci.13768. View

Guo Y, Ding P, Liu L, Shi L, Mao T, Li J . Gegen Qinlian Decoction Attenuates High-Fat Diet-Induced Steatohepatitis in Rats via Gut Microbiota. Evid Based Complement Alternat Med. 2019; 2018:7370891. PMC: 6323455. DOI: 10.1155/2018/7370891. View

Papic N, Jelovcic F, Karlovic M, Stemberger Maric L, Vince A . Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection. Eur J Clin Microbiol Infect Dis. 2019; 39(3):569-574. DOI: 10.1007/s10096-019-03759-w. View

Gurung M, Li Z, You H, Rodrigues R, Jump D, Morgun A . Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine. 2020; 51:102590. PMC: 6948163. DOI: 10.1016/j.ebiom.2019.11.051. View

Bures J, Cyrany J, Kohoutova D, Forstl M, Rejchrt S, Kvetina J . Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010; 16(24):2978-90. PMC: 2890937. DOI: 10.3748/wjg.v16.i24.2978. View

10.

Jin B, Xu F, Ng R, Hogg J . Mian: interactive web-based microbiome data table visualization and machine learning platform. Bioinformatics. 2021; 38(4):1176-1178. DOI: 10.1093/bioinformatics/btab754. View

11.

Prorok-Hamon M, Friswell M, Alswied A, Roberts C, Song F, Flanagan P . Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut. 2013; 63(5):761-70. PMC: 3995253. DOI: 10.1136/gutjnl-2013-304739. View

12.

Mikolasevic I, Delija B, Mijic A, Stevanovic T, Skenderevic N, Sosa I . Small intestinal bacterial overgrowth and non-alcoholic fatty liver disease diagnosed by transient elastography and liver biopsy. Int J Clin Pract. 2021; 75(4):e13947. DOI: 10.1111/ijcp.13947. View

13.

Adenote A, Dumic I, Madrid C, Barusya C, Nordstrom C, Rueda Prada L . NAFLD and Infection, a Nuanced Relationship. Can J Gastroenterol Hepatol. 2021; 2021:5556354. PMC: 8087474. DOI: 10.1155/2021/5556354. View

14.

Domper Bardaji F, Gil Rendo A, Fernandez-Bermejo S, Paton Arenas R, Hernandez Albujar A, Martin Davila F . An assessment of bacterial overgrowth and translocation in the non-alcoholic fatty liver of patients with morbid obesity. Rev Esp Enferm Dig. 2019; 111(4):294-300. DOI: 10.17235/reed.2019.5942/2018. View

15.

Yang T, Santisteban M, Rodriguez V, Li E, Ahmari N, Carvajal J . Gut dysbiosis is linked to hypertension. Hypertension. 2015; 65(6):1331-40. PMC: 4433416. DOI: 10.1161/HYPERTENSIONAHA.115.05315. View

16.

Serrana J, Watanabe K . Sediment-associated microbial community profiling: sample pre-processing through sequential membrane filtration for 16S rRNA amplicon sequencing. BMC Microbiol. 2022; 22(1):33. PMC: 8772107. DOI: 10.1186/s12866-022-02441-0. View

17.

Kitamori K, Naito H, Tamada H, Kobayashi M, Miyazawa D, Yasui Y . Development of novel rat model for high-fat and high-cholesterol diet-induced steatohepatitis and severe fibrosis progression in SHRSP5/Dmcr. Environ Health Prev Med. 2011; 17(3):173-82. PMC: 3348249. DOI: 10.1007/s12199-011-0235-9. View

18.

Eslam M, Sarin S, Wong V, Fan J, Kawaguchi T, Ahn S . The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020; 14(6):889-919. DOI: 10.1007/s12072-020-10094-2. View

19.

Eslam M, Sanyal A, George J . MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312. View

20.

Kanda T, Goto T, Hirotsu Y, Masuzaki R, Moriyama M, Omata M . Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Int J Mol Sci. 2020; 21(4). PMC: 7073210. DOI: 10.3390/ijms21041525. View